Literature DB >> 26927984

Cellular and humoral immunogenicity of recombinant Mycobacterium smegmatis expressing Ag85B epitopes in mice.

Nur-Ayuni Kadir1, Maria E Sarmiento2, Armando Acosta3, Mohd-Nor Norazmi4.   

Abstract

OBJECTIVE/
BACKGROUND: The search for new vaccines more efficacious than bacille Calmette-Guérin for tuberculosis prevention is of paramount importance for the control of the disease. The expression of Mycobacterium tuberculosis antigens in Mycobacterium smegmatis is one of the current strategies for the development of new-generation vaccines against tuberculosis. The objective of this study was to evaluate the immunogenicity in mice of M. smegmatis expressing epitopes from Ag85B antigen.
METHODS: M. smegmatis expressing three T cell epitopes from M. tuberculosis Ag85B (P21, P26, and P53) was constructed (rMs064). rMs064 was used to immunize BALB/C mice for immunogenicity evaluation. The present study investigates the capacity of rMs064 to induce specific cellular and humoral immune responses against the expressed epitopes. Cytokine production upon stimulation with Ag85B peptides and specific total immunoglobulin G and immunoglobulin G subclasses were determined.
RESULTS: The results showed a significant production of interleukin-12 and interleukin-23 when splenocytes were stimulated with P21, P26, and P53 peptides, and interferon-γ after stimulation with P21 in animals immunized with rMs064 compared with controls. The total immunoglobulin G and its subclasses showed significant increases against the Ag85B epitopes in the sera of rMs064-immunized mice compared with the control groups.
CONCLUSION: The results of this study support the future evaluation of rMs064 as a vaccine candidate against tuberculosis in challenge experiments.
Copyright © 2015. Published by Elsevier Ltd.

Entities:  

Keywords:  Ag85B; Cytokine; Epitopes; Mycobacterium smegmatis; Mycobacterium tuberculosis; Tuberculosis

Mesh:

Substances:

Year:  2015        PMID: 26927984     DOI: 10.1016/j.ijmyco.2015.09.006

Source DB:  PubMed          Journal:  Int J Mycobacteriol        ISSN: 2212-5531


  6 in total

Review 1.  The current status, challenges, and future developments of new tuberculosis vaccines.

Authors:  Wenping Gong; Yan Liang; Xueqiong Wu
Journal:  Hum Vaccin Immunother       Date:  2018-05-14       Impact factor: 3.452

2.  The effect of adjuvants and delivery systems on Th1, Th2, Th17 and Treg cytokine responses in mice immunized with Mycobacterium tuberculosis-specific proteins.

Authors:  Hussain A Safar; Abu Salim Mustafa; Hanady A Amoudy; Ahmed El-Hashim
Journal:  PLoS One       Date:  2020-02-06       Impact factor: 3.240

Review 3.  COVID-19 vaccine development: What lessons can we learn from TB?

Authors:  Hussain A Safar; Abu Salim Mustafa; Timothy D McHugh
Journal:  Ann Clin Microbiol Antimicrob       Date:  2020-11-30       Impact factor: 3.944

4.  The Effect of Delivery Systems on the Induction of T Helper 1 Cell Response to an ESAT6-Like Protein Rv3619c and Identification of Its Immunodominant Peptides.

Authors:  Hussain A Safar; Abu Salim Mustafa; Hanady A Amoudy; Ahmed El-Hashim
Journal:  Med Princ Pract       Date:  2022-05-18       Impact factor: 2.132

5.  Potential of recombinant Mycobacterium paragordonae expressing HIV-1 Gag as a prime vaccine for HIV-1 infection.

Authors:  Byoung-Jun Kim; Bo-Ram Kim; Yoon-Hoh Kook; Bum-Joon Kim
Journal:  Sci Rep       Date:  2019-10-29       Impact factor: 4.379

6.  Selection of a Single Domain Antibody, Specific for an HLA-Bound Epitope of the Mycobacterial Ag85B Antigen.

Authors:  Paola A Ortega; Mayra Silva-Miranda; Alfredo Torres-Larios; Eduardo Campos-Chávez; Kees C L C M Franken; Tom H M Ottenhoff; Juraj Ivanyi; Clara Espitia
Journal:  Front Immunol       Date:  2020-10-02       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.